General Information of Drug (ID: DM84ZXF)

Drug Name
Lorazepam
Synonyms
Almazine; Alzapam; Anxiedin; Anxira; Anzepam; Aplacasse; Aplacassee; ApoLorazepam; Aripax; Ativan; Azurogen; Bonatranquan; Bonton; Delormetazepam; Demethyllormetazepam; Donix; Duralozam; Durazolam; Efasedan; Emotion; Emotival; Equitam; Idalprem; Kalmalin; Larpose; Laubeel; Lomesta; Lopam; Lorabenz; Lorafen; Loram; Lorans; Lorapam; Lorat; Lorax; Loraz; Lorazene; Lorazep; Lorazepamum; Lorazin; Lorazon; Lorenin; Loridem; Lorivan; Lorsedal; Lorsilan; Lorzem; Lozepam; Merlit; Nervistopl; Norlormetazepam; Novhepar; Novolorazem; NuLoraz; Orfidal; Punktyl; Quait; Renaquil; Rocosgen; Securit; Sedatival; Sedazin; Sedicepan; Sedizepan; Sidenar; Silence; Sinestron; Somagerol; Stapam; Tavor; Temesta; Tolid; Tranqipam; Trapax; Upan; Vigiten; Wypax; AHP Brand of Lorazepam; Apo Lorazepam; Apotex Brand of Lorazepam; Baxter Brand of Lorazepam; Ct Arzneimittel Brand of Lorazepam; Desitin Brand of Lorazepam; Dolorgiet Brand of Lorazepam; Llorens Brand of Lorazepam; Lorazep von ct; Lorazepam AHP Brand; Lorazepam Apotex Brand; Lorazepam Baxter Brand; Lorazepam Desitin Brand; Lorazepam Dolorgiet Brand; Lorazepam Fabra; Lorazepam Genericon; Lorazepam Intensol; Lorazepam Lannacher; Lorazepam Llorens Brand; Lorazepam Medical; Lorazepam Medical Brand; Lorazepam Medix Brand; Lorazepam Novartis Brand; Lorazepam Novopharm Brand; Lorazepam Riemser Brand; Lorazepam Wyeth Brand; Lorazepam neuraxpharm; Lorazepam neuraxpharm Brand; Lorazepam preservative free; Lorazepam ratiopharm; Lorazepam ratiopharm Brand; Lorazepan Chobet; Lorazepan Richet; Max Pax; Medical Brand of Lorazepam; Medix Brand of Lorazepam; Merck dura Brand of Lorazepam; Nervistop L; Neuraxpharm Brand of Lorazepam; Novartis Brand of Lorazepam; Novo Lorazem; Novopharm Brand of Lorazepam; Nu Loraz; Nu Pharm Brand of Lorazepam; Orfidal Wyeth; Pro dorm; Ratiopharm Brand of Lorazepam; Riemser Brand of Lorazepam; Serra Pamies Brand of Lorazepam; Wyeth Brand of Lorazepam; L1764_SIGMA; WY4036; Wy 4036; Apo-Lorazepam; Ativan (TN); Ct-Arzneimittel Brand of Lorazepam; Lorazepam (Ativan); Lorazepam Nu-Pharm Brand; Lorazepam ct-Arzneimittel Brand; Lorazepam-Efeka; Lorazepam-neuraxpharm; Lorazepam-ratiopharm; Lorazepamum [INN-Latin]; Medical, Lorazepam; Novo-Lorazem; Nu-Loraz; Nu-Pharm Brand of Lorazepam; O-Chlorooxazepam; O-Chloroxazepam; Temesta (TN); Wy-4036; Wyeth, Orfidal; Lorazepam (JP15/USP/INN); Lorazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; (+/-)-Lorazepam; 7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-Chloro-5-(2-chlorophenyl)-3-hydroxy-1H-1,4-benzodiazepin-2(3H)-one; 7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one; 7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
Indication
Disease Entry ICD 11 Status REF
Absence epilepsy N.A. Approved [1]
Anxiety N.A. Approved [1]
Anxiety disorder 6B00-6B0Z Approved [2]
Nausea MD90 Approved [1]
Panic disorder 6B01 Approved [1]
Vomiting MD90 Approved [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Antianxiety Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 321.2
Logarithm of the Partition Coefficient (xlogp) 2.4
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 2.5 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 7 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability
The bioavailability of drug is 29% [3]
Clearance
The clearance of drug is 5.8 mL/min/kg [5]
Elimination
When a single 2 mg oral dose is given to healthy subjects, 88% of the administered dose is recovered in urine and 7% was recovered in feces []
Half-life
The concentration or amount of drug in body reduced by one-half in 14 hours [6]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.4448 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.09% [6]
Vd
The volume of distribution (Vd) of drug is 1.3 L/kg []
Water Solubility
The ability of drug to dissolve in water is measured as 0.08 mg/mL [4]
Chemical Identifiers
Formula
C15H10Cl2N2O2
IUPAC Name
7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one
Canonical SMILES
C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
InChI
InChI=1S/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)
InChIKey
DIWRORZWFLOCLC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3958
ChEBI ID
CHEBI:6539
CAS Number
846-49-1
DrugBank ID
DB00186
TTD ID
D0E0OG
INTEDE ID
DR0978
ACDINA ID
D00375
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Translocator protein (TSPO) TTPTXIN TSPO_HUMAN Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [9]
UDP-glucuronosyltransferase 2B15 (UGT2B15) DENZ6B1 UDB15_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lorazepam (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Altered absorption of Lorazepam due to GI dynamics variation caused by Sodium bicarbonate. Acidosis [5C73] [11]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Lorazepam and Oliceridine. Acute pain [MG31] [12]
Nitazoxanide DMOWLVG Moderate Increased plasma concentration of Lorazepam and Nitazoxanide due to competitive binding of plasma proteins. Bowel habit change [ME05] [13]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Lorazepam and Dihydrocodeine. Chronic pain [MG30] [14]
Morphine DMRMS0L Major Additive CNS depression effects by the combination of Lorazepam and Morphine. Chronic pain [MG30] [12]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Lorazepam and Olopatadine. Conjunctiva disorder [9A60] [15]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Lorazepam and Propofol. Corneal disease [9A76-9A78] [16]
Alfentanil DMVO0UB Major Additive CNS depression effects by the combination of Lorazepam and Alfentanil. Corneal disease [9A76-9A78] [12]
Remifentanil DMZTXCH Major Additive CNS depression effects by the combination of Lorazepam and Remifentanil. Corneal disease [9A76-9A78] [12]
Methadone DMTW6IU Major Additive CNS depression effects by the combination of Lorazepam and Methadone. Cough [MD12] [12]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Lorazepam and Ethanol. Cystitis [GC00] [17]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Lorazepam and Esketamine. Depression [6A70-6A7Z] [18]
SODIUM CITRATE DMHPD2Y Minor Altered absorption of Lorazepam due to GI dynamics variation caused by SODIUM CITRATE. Discovery agent [N.A.] [11]
Mephenytoin DM5UGDK Moderate Increased metabolism of Lorazepam caused by Mephenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Phenytoin DMNOKBV Moderate Increased metabolism of Lorazepam caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Lorazepam caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Ethotoin DMXWOCP Moderate Increased metabolism of Lorazepam caused by Ethotoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [19]
Brimonidine DMQLT4N Moderate Additive CNS depression effects by the combination of Lorazepam and Brimonidine. Glaucoma [9C61] [20]
Digoxin DMQCTIH Moderate Increased plasma concentration of Lorazepam and Digoxin due to competitive binding of plasma proteins. Heart failure [BD10-BD1Z] [21]
Bumetanide DMRV7H0 Moderate Additive hypotensive effects by the combination of Lorazepam and Bumetanide. Heart failure [BD10-BD1Z] [22]
Didanosine DMI2QPE Minor Altered absorption of Lorazepam due to GI dynamics variation caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [11]
Metoprolol DMOJ0V6 Minor Decreased metabolism of Lorazepam caused by Metoprolol. Hypertension [BA00-BA04] [23]
Probenecid DMMFWOJ Minor Decreased metabolism of Lorazepam caused by Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [24]
PF-06463922 DMKM7EW Moderate Increased metabolism of Lorazepam caused by PF-06463922 mediated induction of UGT. Lung cancer [2C25] [18]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Lorazepam and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [25]
Propranolol DM79NTF Minor Decreased metabolism of Lorazepam caused by Propranolol. Migraine [8A80] [23]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Lorazepam and Lasmiditan. Migraine [8A80] [26]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Lorazepam and Flibanserin. Mood disorder [6A60-6E23] [27]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Lorazepam and Thalidomide. Multiple myeloma [2A83] [28]
Droperidol DM0DXA8 Major Increased risk of prolong QT interval by the combination of Lorazepam and Droperidol. Nausea/vomiting [MD90] [29]
Teduglutide DMYOAKS Moderate Altered absorption of Lorazepam caused by Teduglutide. Neonatal malabsorption syndrome [KB89] [30]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Lorazepam and Levomethadyl Acetate. Opioid use disorder [6C43] [14]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Lorazepam and Apraclonidine. Optic nerve disorder [9C40] [20]
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Lorazepam and Pentazocine. Pain [MG30-MG3Z] [12]
Dextropropoxyphene DM23HCX Major Additive CNS depression effects by the combination of Lorazepam and Dextropropoxyphene. Pain [MG30-MG3Z] [31]
Butorphanol DM5KYPJ Major Additive CNS depression effects by the combination of Lorazepam and Butorphanol. Pain [MG30-MG3Z] [12]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Lorazepam and Oxymorphone. Pain [MG30-MG3Z] [12]
Levorphanol DMGS80V Major Additive CNS depression effects by the combination of Lorazepam and Levorphanol. Pain [MG30-MG3Z] [12]
Hydromorphone DMHP21E Major Additive CNS depression effects by the combination of Lorazepam and Hydromorphone. Pain [MG30-MG3Z] [12]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Lorazepam and Dezocine. Pain [MG30-MG3Z] [12]
Codeine DMJX6ZG Major Additive CNS depression effects by the combination of Lorazepam and Codeine. Pain [MG30-MG3Z] [12]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Lorazepam and Nalbuphine. Pain [MG30-MG3Z] [12]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Lorazepam and Buprenorphine. Pain [MG30-MG3Z] [32]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Lorazepam and Hydrocodone. Pain [MG30-MG3Z] [12]
Tramadol DMRQD04 Major Additive CNS depression effects by the combination of Lorazepam and Tramadol. Pain [MG30-MG3Z] [12]
Meperidine DMX4GND Major Additive CNS depression effects by the combination of Lorazepam and Meperidine. Pain [MG30-MG3Z] [12]
Oxycodone DMXLKHV Major Additive CNS depression effects by the combination of Lorazepam and Oxycodone. Pain [MG30-MG3Z] [12]
Fentanyl DM8WAHT Major Additive CNS depression effects by the combination of Lorazepam and Fentanyl. Sensation disturbance [MB40] [12]
Tizanidine DMR2IQ4 Moderate Additive CNS depression effects by the combination of Lorazepam and Tizanidine. Tonus and reflex abnormality [MB47] [33]
Cetirizine DMOMP9U Moderate Additive CNS depression effects by the combination of Lorazepam and Cetirizine. Vasomotor/allergic rhinitis [CA08] [34]
Amiodarone DMUTEX3 Minor Potentiate the pharmacologic effects by the combination of Lorazepam and Amiodarone. Ventricular tachyarrhythmia [BC71] [35]
⏷ Show the Full List of 51 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sodium stearyl fumarate E00545 23665634 lubricant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lorazepam 0.5 mg tablet 0.5 mg Oral Tablet Oral
Lorazepam 1 mg tablet 1 mg Oral Tablet Oral
Lorazepam 2 mg tablet 2 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Lorazepam FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5884).
3 Matzke GR, Zhanel GG, Guay DR: Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986 Jul-Aug;11(4):257-82. doi: 10.2165/00003088-198611040-00001.
4 BDDCS applied to over 900 drugs
5 Li C, Liu T, Cui X, Uss AS, Cheng KC: Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen. 2007 Dec;12(8):1084-91. doi: 10.1177/1087057107308892. Epub 2007 Nov 7.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
10 Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94.
11 Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
12 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
13 Product Information. Alinia (nitazoxanide). Romark Laboratories L.C., Tampa, FL.
14 US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
15 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
16 Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
17 Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
18 Cerner Multum, Inc. "Australian Product Information.".
19 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
20 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
21 Castillo-Ferrando JR, Garcia M, Carmona J "Digoxin levels and diazepam." Lancet 2 (1980): 368. [PMID: 6105500]
22 Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
23 Hawksworth G, Betts T, Crowe A, et al "Diazepam/beta-adrenoceptor antagonist interactions." Br J Clin Pharmacol 17 Suppl 1 (1984): s69-76. [PMID: 6146341]
24 Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
25 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
26 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
27 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
28 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
29 Canadian Pharmacists Association.
30 Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
31 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
32 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
33 Product Information. Zanaflex (tizanidine). Acorda Therapeutics, Hawthorne, NY.
34 Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.
35 Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]